清肺化瘀解毒方对非小细胞肺癌细胞耐药的逆转作用研究OA
Study on the reversal effect of Qingfei huayu jiedu formula on drug resistance in non-small cell lung cancer cells
目的 基于微RNA-641(miR-641)/胞外信号调节激酶(ERK)信号通路,探讨清肺化瘀解毒方(QFHYJDF)对非小细胞肺癌(NSCLC)细胞耐药的逆转作用.方法 以人NSCLC亲本细胞A549为对象,采用浓度梯度递增联合高浓度冲击策略构建吉非替尼耐药细胞系A549/GR.在筛选干预浓度及时间后,将耐药细胞分为对照血清组(20%空白血清作用48 h)、QFHYJDF含药血清组(20%QFHYJDF含药血清作用48 h)和常规培养组(常规培养48 h),检测各组细胞的相对活力和总凋亡率,以及细胞中miR-641和神经纤维蛋白1(NF1)、ERK1/2、磷酸化ERK1/2(p-ERK1/2)的表达水平.结果 与常规培养组和对照血清组比较,QFHYJDF含药血清组细胞的相对活力均显著降低,总凋亡率均显著升高,细胞中NF1蛋白的表达均显著上调,miR-641和p-ERK1、p-ERK2蛋白的表达均显著下调(P<0.05).结论 QFHYJDF可抑制吉非替尼耐药肺癌细胞的增殖,促进其凋亡,上述作用可能与上调NF1蛋白表达、抑制miR-641表达及ERK信号通路活性有关.
OBJECTIVE To investigate the reversal effect of Qingfei huayu jiedu formula(QFHYJDF)on drug resistance in non-small cell lung cancer(NSCLC)cells based on the microRNA-641(miR-641)/extracellular signal-regulated kinase(ERK)signaling pathway.METHODS The human parental NSCLC cell line A549 was used to establish gefitinib-resistant cells A549/GR by combining concentration gradient increment with high-concentration pulse strategy.After screening for optimal intervention concentration and duration,the resistant cells were divided into a control serum group(treated with 20%blank serum for 48 h),QFHYJDF-containing serum group(treated with 20%QFHYJDF-containing serum for 48 h),and the normally cultured group(normally cultured for 48 h).The cell relative viability,total apoptosis rate,as well as the expression levels of miR-641,neurofibromin 1(NF1),ERK1/2,and phosphorylated ERK1/2(p-ERK1/2),were assessed in each group.RESULTS Compared with the normally cultured group and the control serum group,the QFHYJDF-containing serum group exhibited significantly decreased cell relative viability and significantly increased total apoptosis rate(P<0.05).Moreover,the expression of NF1 protein was significantly up-regulated,while the expression levels of miR-641 and p-ERK1,p-ERK2 proteins were significantly down-regulated in the QFHYJDF-containing serum group(P<0.05).CONCLUSIONS QFHYJDF can inhibit proliferation and promote apoptosis of gefitinib-resistant lung cancer cells,which may be associated with up-regulating NF1 protein expression,down-regulating miR-641 expression,and inhibiting the activity of the ERK signaling pathway.
陈帅龙;刘慧慧;桑锋;蒋立峰
河南中医药大学第一附属医院血液肿瘤科,郑州 450003||中西医防治重大疾病河南省协同创新中心,郑州 450003河南中医药大学第一附属医院血液肿瘤科,郑州 450003||中西医防治重大疾病河南省协同创新中心,郑州 450003河南中医药大学第一附属医院艾滋病临床研究中心,郑州 450003河南省肿瘤医院中西医结合科,郑州 450008
医药卫生
清肺化瘀解毒方非小细胞肺癌吉非替尼耐药miR-641/ERK信号通路
Qingfei huayu jiedu formulanon-small cell lung cancergefitinib resistancemiR-641/ERK signaling pathway
《中国药房》 2026 (12)
1553-1558,6
国家自然科学基金联合基金项目(No.U1704181)河南省卫生健康委国家中医临床研究基地科研专项(No.2022JDZX1-53)河南省中医药科学研究专项课题(No.2023ZY2201)河南省协同创新中心(中西医防治重大疾病协同创新中心)项目(No.教科技[2023]413号)
评论